Overview
Ovarian aging (OA) seriously affects the physical and mental health of women. Nowadays, Chinese herbs have huge appeal and potential in treating OA. We have created a new Chinese herbal combination Yijing Keli, whereas its safety and efficacy still need to be validated. Hence, we will perform a population-based, multicenter study to confirm the safety and efficacy of Yijing Keli in therapy of OA. We aim to provide a solid evidence for TCM in therapy of OA.
Eligibility
Inclusion Criteria:
- The age range of patient is 18-55 years old.
- The diagnostic criteria for ovarian aging.
- Sign the informed consent form.
Exclusion Criteria:
- Patient is known to be allergic or unsuitable for the Chinese herbal compound.
- Women who are pregnant and lactating.
- Abnormal uterine bleeding, except ovulation disorders.
- Women is taking hormone drugs and has stopped taking them within 3 months;
- Women with endometriosis, myadenosis, submucosal fibroids or the size of nonsubmucosal fibroids is more than 4 cm.
- The nature of pelvic mass is unknown.
- Women with polycystic ovary syndrome, hyperprolactinemia, hyperandrogenemia, diabetes, thyroid and adrenal dysfunction and other endocrine diseases affecting ovulation.
- Patients with serious primary diseases such as cardiovascular, liver, kidney, lung, biliary, hematopoietic system (Hb<90g/L) and malignant tumor, and psychiatric patients.
- Patients are participating in other clinical trials or have participated in other clinical trials within the last month.
- Unsuitable for the study evaluated by the investigator.